TTrialPathMatch Me to Trials
← Back to trials
RecruitingPost-ligation Cardiac Syndrome

Milrinone for Prevention of Post-ligation Cardiac Syndrome Trial

Eligible age

Up to 0.3 yrs

Accepts

All genders

Locations

15 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The goal of this Phase 3, randomized, masked clinical trial is to is to find out whether milrinone, when given to infants after PDA closure, will help the heart work better by supplying oxygen to the lungs and tissues. The main questions it aims to answer are: 1. to determine if milrinone decreases the risk of death or PLCS within 7 days of the procedure, compared to standard treatment; and 2. to determine the effects of milrinone on two-year survival and neurodevelopmental outcome.

Sponsor: NICHD Neonatal Research Network

You may qualify if…

  • ✓ Gestational age at birth ≤27 weeks (and 6 days) and postnatal age \< 3 months at intervention
  • ✓ Invasive or non-invasive positive pressure respiratory support (does not include low flow nasal cannula)
  • ✓ Hemodynamically significant PDA with minimum transductal diameter ≥1.0 mm within 2 days of intervention
  • ✓ Decision by clinical team to proceed with PDA closure via surgical ligation or percutaneous cardiac catheterization based on clinical and echocardiography features of hemodynamic significance.

You may not qualify if…

  • ✕ Any major congenital malformation
  • ✕ Congenital heart disease (except small (≤1mm) muscular ventricular septal defects, or small/moderate (\<3mm) atrial septal defect)
  • ✕ Acute renal failure defined by urine output \< 0.5 mL/kg/hour OR rise of serum creatinine by 0.3 mg/dL within 48 hours OR rise of serum creatinine more than 40% above baseline serum creatinine within prior 72 hours.
  • ✕ Systemic administration of vasodilator/inodilator agents
  • ✕ Prior history of arrhythmia

Where it's recruiting

Alabama

Birmingham

California

Orange · Palo Alto · San Diego

Georgia

Atlanta

Illinois

Chicago

Iowa

Iowa City

New Mexico

Albuquerque

Ohio

Cincinnati · Cleveland

Oklahoma

Oklahoma City

Pennsylvania

Philadelphia

Source: ClinicalTrials.gov · NCT06679855 · last updated 2026-07-01

Milrinone for Prevention of Post-ligation Cardiac Syndrome Trial · TrialPath